Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Whelan

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 11, 2011
Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trialsHans Gelderblom, Rachel C Jinks, Matthew Sydes, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2016
Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G groupStéphanie Foulon, Bernadette Brennan, Nathalie Gaspar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2013
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysisMarnie Collins, Miriam Wilhelm, Rachel Conyers, et al.
British Journal of Cancer|March 15, 2026
Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trialBrennan Bernadette, Laura Kirton, Perrine Marec-Bérard, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|July 11, 2021
Reporting the whole story: Analysis of the 'out-of-scope' questions from the James Lind Alliance Teenage and Young Adult Cancer Priority Setting Partnership SurveyFaith Gibson, Lorna A Fern, Bob Phillips, et al.
Trials|January 19, 2020
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 ProtocolJennifer Anderton, Veronica Moroz, Perrine Marec-Bérard, et al.
Journal of the National Cancer Institute|January 18, 2007
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma IntergroupIan J Lewis, Marianne A Nooij, Jeremy Whelan, et al.
Circulation|November 9, 2016
Cardiac Mortality Among 200 000 Five-Year Survivors of Cancer Diagnosed at 15 to 39 Years of Age: The Teenage and Young Adult Cancer Survivor StudyKatherine E Henson, Raoul C Reulen, David L Winter, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2022
Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcomaAxel Budde, Katja Baust, Leonie Weinhold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2008
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patientsMichael Paulussen, Alan W Craft, Ian Lewis, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
European Journal of Cancer (Oxford, England : 1990)|January 11, 2011
Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trialsHans Gelderblom, Rachel C Jinks, Matthew Sydes, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2016
Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G groupStéphanie Foulon, Bernadette Brennan, Nathalie Gaspar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2013
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysisMarnie Collins, Miriam Wilhelm, Rachel Conyers, et al.
British Journal of Cancer|March 15, 2026
Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trialBrennan Bernadette, Laura Kirton, Perrine Marec-Bérard, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|July 11, 2021
Reporting the whole story: Analysis of the 'out-of-scope' questions from the James Lind Alliance Teenage and Young Adult Cancer Priority Setting Partnership SurveyFaith Gibson, Lorna A Fern, Bob Phillips, et al.
Trials|January 19, 2020
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 ProtocolJennifer Anderton, Veronica Moroz, Perrine Marec-Bérard, et al.
Journal of the National Cancer Institute|January 18, 2007
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma IntergroupIan J Lewis, Marianne A Nooij, Jeremy Whelan, et al.
Circulation|November 9, 2016
Cardiac Mortality Among 200 000 Five-Year Survivors of Cancer Diagnosed at 15 to 39 Years of Age: The Teenage and Young Adult Cancer Survivor StudyKatherine E Henson, Raoul C Reulen, David L Winter, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2022
Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcomaAxel Budde, Katja Baust, Leonie Weinhold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2008
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patientsMichael Paulussen, Alan W Craft, Ian Lewis, et al.
Pageof 9